Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ligand Earns SAGE Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Ligand Earns SAGE Milestone

Initiates Phase III Trial

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ligand Pharmaceuticalshas earned a $500,000 milestone payment from SAGE Therapeutics relating to the initiation of SAGE’s Phase III study to evaluate the safety of SAGE-547 in patients with super-refractory status epilepticus (SRSE).
 
Results from this trial, along with results from SAGE’s planned Phase III placebo-controlled trial, and other clinical data from the SAGE-547 development program will be used for an New Drug Application (NDA) submission. 
 
Ligand entered into a Captisol license agreement with SAGE for the development and commercialization of SAGE-547 in 2011. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics